Research Status of Postoperative Adjuvant Therapy for Hepatocellular Carcinoma
Hepatocellular carcinoma(HCC),referred to as liver cancer,is the fifth and second malignant tumor in China in terms of incidence and mortality,respectively.Postoperative recurrence of liver cancer seriously affects the prognosis of patients,and postoperative adjuvant therapy is an important means to prevent the recurrence of liver cancer.Although domestic and foreign studies have confirmed that some adjuvant therapy protocols can delay postoperative recurrence,prolong survival time and improve prognosis of patients,there is also a consensus of experts in China to recommend a variety of adjuvant therapy protocols,including antiviral therapy,targeted therapy,immunotherapy,transcatheter arterial chemoembolization(TACE),hepatic arterial infusion chemotherapy(HAIC),traditional Chinese medicine treatment,etc.However,the application value of adjuvant therapy after liver cancer surgery in the comprehensive treatment of liver cancer is not completely clear,and the beneficiary population of adjuvant therapy can not be accurately positioned,so the necessity of adjuvant therapy after liver cancer surgery is still controversial.This article will review the research on postoperative adjuvant therapy for liver cancer at home and abroad.
Hepatocellular carcinomaAfter liver cancer surgeryRecurrenceAdjuvant therapy
国家科技期刊平台
NSTL
万方数据
